UNC Lineberger researchers say the findings of a new study published in the journal Quality of Life Research indicate that activity trackers could be a useful tool for tracking symptoms and physical function. These trackers may be especially useful for patients who are not able to self-report symptoms using questionnaires because of language barriers, literacy, cognitive or health status.
Researchers surveyed more than 700 pediatricians and family physicians about their recommendations for the HPV vaccine, finding that 27 percent did not strongly endorse the vaccine. The findings are significant as low uptake of HPV vaccination is contributing to a national crisis in cancer prevention, said UNC Lineberger researcher and study senior author Noel Brewer.
UNC Lineberger researcher Stephen Hursting, PhD, MPH is a recipient of the NCI Outstanding Investigator Award for 2015. Hursting was in the first class of recipients of the seven-year grant award, which supports investigators with outstanding records of productivity in cancer research by providing extended funding stability and encouraging investigators to continue or embark on projects of unusual potential in cancer research.
A study published in JAMA Oncology found that pre-menopausal women who were diagnosed with breast cancer following a biennial screening mammogram were likely to have more advanced tumors than woman screened annually. UNC Lineberger researcher Louise Henderson was a co-author on the study, which was co-led by researchers at the University of California-Davis School of Medicine and the Dana-Farber Cancer Institute.
A research team led by Drs. Adrienne D. Cox and Channing J. Der (members of the UNC Lineberger Program in Molecular Therapeutics) is one of the first recipients of an NCI U01 grant on New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers. Their team, which also includes Drs. Ben Major at UNC, Kris Wood at Duke and Krister Wennerberg at FIMM, will pursue novel genetic screens to search for the long-elusive effective anti-KRAS cancer treatment.